Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...
The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat Huntington’s disease.
Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external cont ...
Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive ...
News-Medical.Net on MSN
Review shows lecanemab and donanemab slow decline and explains who should get them
The Lancet review synthesises evidence on anti beta amyloid monoclonal antibodies and the wider Alzheimer’s care pathway, ...
About 60% of all outstanding mortgages in Canada are expected to renew in 2025 or 2026. In this note, we provide an updated assessment of how mortgage payments may change for these households at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback